What is the utility of remibrutinib or other tyrosine kinase inhibitors in MCAS?

MCAS can be due to clonal (mastocytosis) or non-clonal (IgE and non-IgE mediated mast cell activation or idiopathic) etiologies. Remibrutinib is a btk inhibitor, currently only approved for chronic spontaneous urticaria, but not for MCAS. Btk is involved in IgE receptor signal transduction. In patie...